Tax savings make Bill Ackman cut his firm’s stake in Valeant
Citing tax reasons, Bill Ackman, the activist investor and a strong defender of Valeant Pharmaceuticals International, has reduced his firm’s stake in the drug company. In a regulatory filing, More...
Reuters Exclusive: Valeant considers selling contact lens maker Paragon – sources
Valeant Pharmaceuticals is reaching out to potential buyers for its specialty contact lens manufacturing division, Paragon Vision Sciences, amid scrutiny from the Federal Trade Commission, according to More...
Valeant, Ackman must face U.S. insider trading lawsuit
A U.S. judge said Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N) and activist hedge fund manager William Ackman must face a lawsuit accusing them of insider trading in Allergan Inc before More...
Bill Ackman Defends Pershing Square’s Losses in Valeant Investment
From 2010, Valeant shares rose more than 10-fold to peak in August. Unfortunately, from a systemic perspective, just about every American is worse off as a result of Valeant’s strategy. Still, Valeant More...
Goldman sold 1.3 million Valeant shares backing loan to CEO, Valeant says
Valeant Issues Statement On Sales Of Company Stock as follow: Valeant Pharmaceuticals International, Inc. stated that 1, 297, 399 shares pledged to Goldman Sachs to secure loans made to chairman and More...
Bill Ackman Joins Ranks of Most Successful Hedge Fund Managers
Besides climbing to the top of the hedge fund world, activist investor Bill Ackman has become one of the most successful hedge fund managers of all time after his Pershing Square made huge profits from big bets More...
Alpha Wolf Bill Ackman Is Top Dog on Wall Street
Bill Ackman might be controversial, but he had the top performing hedge fund of 2014, as reported by Bloomberg. While he was ridiculed the previous year for his pressure to put Ron Johnson of AppleStores as More...
Is Bill Ackman Guilty of Insider Trading?
Bill Ackman has cleaned up this year to the tune of $1 billion. He has also profited from Actavis’ announced merger with Botox maker Allergan, although for many months, he was pushing the company to accept More...
Exclusive: Valeant to drop deal-making in near term to cut debt, boost stock
– Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making More...
Actavis Saves Allergan from Valeant Hostile Takeover with $66 Billion Deal, But Will Slash R&D
The seven-month battle over American Botox haven pharmaceutical company Allergan is over, after it accepted a friendly takeover bid from Irish integrated specialty pharmaceutical Actavis. The Actavis offer More...